Delving into the Latest Updates on Onametostat with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

PRMT5

Mechanism

PRMT5 inhibitors(Protein arginine methyltransferase 5 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

Microsatellite Instability cancerAdvanced cancerAdvanced Malignant Solid Neoplasm+ [2]

Inactive Indication-

Originator Organization

Janssen Research & Development LLC

Active Organization

Janssen Research & Development LLCJanssen R&D Ireland Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC22H23BrN6O2

InChIKeyDBSMLQTUDJVICQ-CJODITQLSA-N

CAS Registry2086772-26-9

The purpose of the study is to identify the maximum tolerated dose (MTD) of JNJ-64619178 in participants with relapsed/refractory B cell non-Hodgkin lymphoma (NHL) or advanced solid tumors and also to identify the recommended Phase 2 dose(s) (RP2Ds) of JNJ-64619178 for NHL and advanced solid tumors (Part 1) and to confirm the tolerability of JNJ-64619178 in participants with lower risk myelodysplastic syndromes (MDS) (Part 2).

Start Date13 Jul 2018

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with Onametostat

Login to view more data

100 Translational Medicine associated with Onametostat

Login to view more data

100 Patents (Medical) associated with Onametostat

Login to view more data

13

Literatures (Medical) associated with Onametostat

08 Oct 2024·Antimicrobial Agents and Chemotherapy

Onametostat, a PfPRMT5 inhibitor, exhibits antimalarial activity to Plasmodium falciparum

Article

Author: Madsen, Jesper J. ; Chim-Ong, Anongruk ; Lucky, Amuza Byaruhanga ; Miao, Jun ; Cui, Liwang ; Min, Hui ; Li, Xiaolian

ABSTRACT Protein arginine methyltransferases (PRMTs) play critical roles in Plasmodium falciparum , a protozoan causing the deadliest form of malaria, making them potential targets for novel antimalarial drugs. Here, we screened 11 novel PRMT inhibitors against P. falciparum asexual growth and found that onametostat, an inhibitor for type II PRMTs, exhibited strong antimalarial activity with a half-maximal inhibitory concentration (IC 50 ) value of 1.69 ± 0.04 µM. In vitro methyltransferase activities of purified PfPRMT5 were inhibited by onametostat, and a shift of IC 50 to onametostat was found in the PfPRTM5 disruptant parasite line, indicating that PfPRTM5 is the primary target of onametostat. Consistent with the function of PfPRMT5 in mediating symmetric dimethylation of histone H3R2 (H3R2me2s) and in regulating invasion-related genes, onametostat treatment led to the reduction of H3R2me2s level in P. falciparum and caused the defects on the parasite’s invasion of red blood cells. This study provides a starting point for identifying specific PRMT inhibitors with the potential to serve as novel antimalarial drugs.

29 Jan 2024·Oncogene

MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression

Article

Author: Jayatilleke, Nisitha ; Cheung, Belamy B ; Speleman, Frank ; Mayoh, Chelsea ; Salib, Alice ; Seneviratne, Janith A ; De Preter, Katleen ; Marshall, Glenn M ; Carter, Daniel R

AbstractMany of the pro-tumorigenic functions of the oncogene MYCN are attributed to its regulation of global gene expression programs. Alternative splicing is another important regulator of gene expression and has been implicated in neuroblastoma development, however, the molecular mechanisms remain unknown. We found that MYCN up-regulated the expression of the core spliceosomal protein, SNRPD3, in models of neuroblastoma initiation and progression. High mRNA expression of SNRPD3 in human neuroblastoma tissues was a strong, independent prognostic factor for poor patient outcome. Repression of SNRPD3 expression correlated with loss of colony formation in vitro and reduced tumorigenicity in vivo. The effect of SNRPD3 on cell viability was in part dependent on MYCN as an oncogenic co-factor. RNA-sequencing revealed a global increase in the number of genes being differentially spliced when MYCN was overexpressed. Surprisingly, depletion of SNRPD3 in the presence of overexpressed MYCN further increased differential splicing, particularly of cell cycle regulators, such as BIRC5 and CDK10. MYCN directly bound SNRPD3, and the protein arginine methyltransferase, PRMT5, consequently increasing SNRPD3 methylation. Indeed, the PRMT5 inhibitor, JNJ-64619178, reduced cell viability and SNRPD3 methylation in neuroblastoma cells with high SNRPD3 and MYCN expression. Our findings demonstrate a functional relationship between MYCN and SNRPD3, which maintains the fidelity of MYCN-driven alternative splicing in the narrow range required for neuroblastoma cell growth. SNRPD3 methylation and its protein-protein interface with MYCN represent novel therapeutic targets.

01 Nov 2023·Leukemia Research

Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

Article

Author: Brunner, Andrew M ; Haque, Tamanna ; Alfonso-Pierola, Ana ; Mehta, Jaydeep ; Brown, Regina J ; Patel, Manish R ; Chromik, Jöerg ; Valcárcel, David ; Cadenas, Felix López ; Lauring, Josh ; Morillo, Daniel ; Platzbecker, Uwe ; Falantes, Jose ; Germing, Ulrich ; Pastore, Friederike ; Avivi, Irit ; Kalota, Anna ; Mistry, Pankaj ; Xicoy, Blanca ; Gu, Junchen ; Preis, Meir ; Lenox, Laurie ; Leitch, Heather A

Splicing factor (SF) gene mutations are frequent in myelodysplastic syndromes (MDS), and agents that modulate RNA splicing are hypothesized to provide clinical benefit. JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, was evaluated in patients with lower-risk (LR) MDS in a multi-part, Phase 1, multicenter study. The objectives were to determine a tolerable dose and to characterize safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity. JNJ-64619178 was administered on a 14 days on/7 days off schedule or every day on a 21-day cycle to patients with International Prognostic Scoring System (IPSS) Low or Intermediate-1 risk MDS who were red blood cell transfusion-dependent. Twenty-four patients were enrolled; 15 (62.5 %) patients had low IPSS risk score, while 18 (75.0 %) had an SF3B1 mutation. Median duration of treatment was 3.45 months (range: 0.03-6.93). No dose limiting toxicities were observed. The 0.5 mg once daily dose was considered better tolerated and chosen for dose expansion. Twenty-three (95.8 %) patients experienced treatment-emergent adverse events (TEAE). The most common TEAEs were neutropenia (15 [62.5 %]) and thrombocytopenia (14 [58.3 %]). JNJ-64619178 pharmacokinetics was dose-dependent. Target engagement as measured by plasma symmetric di-methylarginine was observed across all dose levels; however, variant allele frequency of clonal mutations in bone marrow or blood did not show sustained reductions from baseline. No patient achieved objective response or hematologic improvement per International Working Group 2006 criteria, or transfusion independence. A tolerable dose of JNJ-64619178 was identified in patients with LR MDS. However, no evidence of clinical benefit was observed.

100 Deals associated with Onametostat

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced cancer	Phase 1	ES	Janssen Research & Development LLC	13 Jul 2018
Advanced cancer	Phase 1	DE	Janssen Research & Development LLC	13 Jul 2018
Advanced cancer	Phase 1	US	Janssen Research & Development LLC	13 Jul 2018
Advanced cancer	Phase 1	IL	Janssen Research & Development LLC	13 Jul 2018
Advanced cancer	Phase 1	CA	Janssen Research & Development LLC	13 Jul 2018
Non-Hodgkin Lymphoma	Phase 1	IL	Janssen Research & Development LLC	13 Jul 2018
Non-Hodgkin Lymphoma	Phase 1	ES	Janssen Research & Development LLC	13 Jul 2018
Non-Hodgkin Lymphoma	Phase 1	DE	Janssen Research & Development LLC	13 Jul 2018
Non-Hodgkin Lymphoma	Phase 1	CA	Janssen Research & Development LLC	13 Jul 2018
Non-Hodgkin Lymphoma	Phase 1	US	Janssen Research & Development LLC	13 Jul 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03573310 (ESMO2020) Manual	Phase 1	Advanced cancer	54	JNJ-64619178	(ahckdwpcxn) = thrombocytopenia, at 3 and 4 mg intermittently and 2 mg QD dcitzkwzbn (lpeorltcbt ) View more	Positive	18 Sep 2020